Safety warnings relating to the risk for QT interval prolongation and torsades de pointes have been added to the Zithromax and Zmax drug labels.
Researchers have a found a dose-response association with citalopram, escitalopram, amitriptyline and QT interval prolongation.
S-ICD is indicated for patients at risk of ventricular tachyarrhythmias who do not require a pacemaker or pacing therapy.
The FDA is reviewing the risk for sudden cardiac death among patients taking azithromycin.
The FDA has issued a warning that the heart drug dronedarone (Multaq) should not be prescribed to patients with permanent atrial fibrillation because of an increased risk of serious cardiovascular events, including death.
Nonsteroidal anti-inflammatory drugs have been linked with increased risk for atrial fibrillation and adverse events in patients with hypertension and coronary artery disease.
The FDA lowered the maximum dose of the antidepressant citalopram hydrobromide (Celexa) from 60 mg per day to 40 mg per day, after concerns that higher doses of the medication increase the risk for cardiac arrhythmia without offering therapeutic benefits.
Atrial fibrillation (AF) affects an estimated 2.3 million Americans and is becoming more widespread as the population ages. Read about guideline changes that simplify treating AF in primary care.
A specialist recommended placement of an implantable cardioverter-defibrillator, but the patient chose to wait and see.
Incidence of severe cardiovascular events and death similar among children and teens that use ADHD medications and those who do not, study finds.